Our Phase 1-3 exploratory and confirmatory trials include advanced design as the new norm! They incorporate "Succeed or fail-fast", "biomarker-driven", "adaptive design", "surrogate outcome", "risk-based", "basket / umbrella trials", "N-of-1 studies" strategies and more to maximize information and success, while minimizing risk and costs.
Syreon Research Institute combines rigorous sources of information, from systematic reviews and meta-analysis to detailed cost-and-outcome studies and economic modeling, to provide robust evidence of economic value. Value dossiers integrate this information to provide the foundation for reimbursement models and tailor-made presentations to payers.
Shorter product cycles and intense competition, already important threats to new pharmaceutical products or diagnostics and devices, are now joined by performance-based pricing as the emerging reimbursement model for new and expensive medications. Our studies provide rapid proof of clinical performance, vital in this payer environment.